# Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)

> **NCT06844422** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 37 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Ivonescimab

## Key facts

- **NCT ID:** NCT06844422
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-08
- **Primary completion:** 2028-02-18
- **Final completion:** 2028-02-18
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06844422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06844422, "Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06844422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*